Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients

Melanie Roch, Maria Celeste Varela, Agustina Taglialegna, Warren E. Rose, Adriana E. Rosato
Melanie Roch
aDepartment of Pathology and Genomic Medicine, Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Celeste Varela
aDepartment of Pathology and Genomic Medicine, Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agustina Taglialegna
aDepartment of Pathology and Genomic Medicine, Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Warren E. Rose
bSchool of Pharmacy, University of Wisconsin—Madison, Madison, Wisconsin, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adriana E. Rosato
aDepartment of Pathology and Genomic Medicine, Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00956-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Time-kill curves of CF strains AMT 0307-5 (MSSA), AMT 0012-33, WIS 664 (MRSA), and TMH 5007 (MRSA CPTr), determined using the following human peak free serum drug concentrations: 8 mg/liter for TLV, 16 mg/liter for VAN, 10.4 mg/liter for LZD, and 16 mg/liter for CPT. The limit of detection of that assay was 10.

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    Comparison of virulence of S. aureus strains and their isogenic TLV-resistant mutants in G. mellonella model of infection. The worms were infected at a dose of 106 bacteria per worm. Survival was monitored for 10 days.

Tables

  • Figures
  • TABLE 1

    Telavancin MIC90 of CPT for 333 S. aureus strains from CF patientsa

    StrainMIC (μg/ml)b
    CPTTLVDAPVANLZD
    MSSA (n = 180)0.5 (100)0.06 (100)0.25 (100)1.0 (100)1–2 (99.4)
    MRSA (n = 153)
        CPTs (n = 130)<1.5 (85)
        CPTir (n = 20)1.5–2 (13)0.06 (100)0.5–1 (100)1–1.5 (100)1–2 (98.1)
        CPThr (n = 3)>32 (2)
    • ↵a The MIC90 of CPT was determined by the microdilution method in Mueller-Hinton broth supplemented with polysorbate 80 (0.002%) and was compared to the MIC90s of the DAP, VAN, LZD, and CPT agents following CLSI guidelines.

    • ↵b Values in parentheses represent the percentage of isolates with the indicated MIC.

  • TABLE 2

    MICs of TLV, VAN, and DAP for the parent strains and in vitro-derived TLVr mutants obtained by serial passage with subinhibitory concentrations of TLV for 40 daysa

    StrainMIC (μg/ml)
    Day 0Day 40
    TLVVANDAPTLVVANDAP
    ATCC 259130.0641.50.25348
    TMH 50070.04720.751.568
    AMT 0114-480.04720.75266
    WIS 6640.032211.536
    • ↵a As shown, a 3- to 4-fold increase in the VAN MIC (from 1.5 to 6 μg/ml) and an 8- to 10-fold increase in DAP MICs (0.25 to 8 μg/ml) were determined, suggesting potential cross-resistance between TLV, VAN, and DAP antibiotics.

  • TABLE 3

    Most relevant mutations identified in telavancin-resistant mutants

    GeneLocusFunctionaSNPAmino acid change
    TMH 5007AMT 0114-48ATCC 25913WIS 664Seattle_90
    acuCSA1556NAD-independent protein deacetylase AcuCA>TA>TA>TA>TA>TI159L
    adh1SA0562Alcohol dehydrogenaseG>TG>TG>TG>TG>TK325N
    aldSA1531Alanine dehydrogenaseG>AG>AG>AG>AG>AS126L
    capBSA0145Capsular polysaccharide synthesis enzyme Cap5AT>CT>CT>CT>CT>CC81R
    ebhASA1267Putative staphylococcal surface-anchored proteinA>GA>GA>GA>GA>GV4497A
    fniSA2136Isopentenyl diphosphate delta-isomerase, FMN dependentG>CG>CG>CG>CG>CR88G
    gltBSA0430Glutamate synthase (NADPH) large chainT>CT>CT>CT>CT>CV1177A
    holASA1415DNA polymerase III delta subunit (EC 2.7.7.7)T>GT>GT>GT>GT>GK45T
    hsdMSA0391Type I restriction-modification system, DNA methyltransferase subunit MT>CT>CT>CT>CT>CV387A
    lacESA1992PTS system, lactose-specific IIB componentT>CT>CT>CT>CT>CI365 M
    lytH, SA1459SA1458LytH protein involved in methicillin resistance/N-acetT>CT>CT>CT>CT>CI1F
    mutS2SA0991Recombination inhibitory protein MutS2G>AG>AG>AG>AG>AV252I
    pbp2SA1283Multimodular transpeptidase-transglycosylaseG>AG>AG>AG>AG>AC197Y
    pbuXSA0374Xanthine permeaseT>GT>GT>GT>GT>GL231V
    pgmSA07302,3-Bisphosphoglycerate-independent phosphoglycerate mutaseA>GA>GA>GA>GA>GT250A
    rhoSA1923Transcription termination factor RhoT>GT>GT>GT>GT>GI48L
    rplASA0496LSU ribosomal protein L1p (L10Ae)A>GA>GA>GA>GA>GT92A
    rpsQSA2038SSU ribosomal protein S17pT>AT>AT>AT>AT>AI77L
    sigASA1390RNA polymerase sigma factor RpoDC>TC>TC>TC>TC>TV253I
    sdrCSA0519Adhesin of unknown specificity SdrCG>AG>AG>AG>AG>AE75K
    sdrDSA0520Adhesin of unknown specificity SdrDG>TG>TG>TG>TG>TD1141Y
    sucASA12452-Oxoglutarate dehydrogenase E1 componentT>GT>GT>GT>GT>GK842N
    tagGSA0594Teichoic acid translocation permease protein TagGT>CT>CT>CT>CT>CV227A
    tcaASA2146Membrane protein TcaA, associated with teicoplanin resistanceA>GA>GA>GA>GA>GL218P
    thrSSA1506Threonyl-tRNA synthetaseC>TC>TC>TC>TC>TG60E
    trePSA0432PTS system, trehalose-specific IIB componentC>GC>GC>GC>GC>GA381G
    uvrASA0714Excinuclease ABC subunit AT>CT>CTA>CGT>CTA>CGL857P
    murQSA0185N-Acetylmuramic acid 6-phosphate etheraseC>TG257D
    clfASA0742Clumping factor ClfA, fibrinogen-binding proteinC>AP208T
    dltASA0793d-Alanine–poly(phosphoribitol) ligase subunit 1A>GK177E
    dltASA0793d-Alanine–poly(phosphoribitol) ligase subunit 1G>AS275N
    dltASA0793d-Alanine–poly(phosphoribitol) ligase subunit 1T>CL318P
    dltASA0793d-Alanine–poly(phosphoribitol) ligase subunit 1C>AD327E
    dltDSA0796Poly(glycerophosphate chain) d-alanine transfer protein DltDT>AI264K
    dltDSA0796Poly(glycerophosphate chain) d-alanine transfer protein DltDT>AD350E
    spaSA0107Protein A, von Willebrand factor binding protein SpaCC>TTG321N
    spaSA0107Protein A, von Willebrand factor binding protein SpaT>GK274N
    spaSA0107Protein A, von Willebrand factor binding protein SpaGT>AGN234T
    • ↵a FMN, flavin mononucleotide; PTS, phosphotransferase; N-acet, N-acetyl; LSU, long subunit; SSU, short subunit.

PreviousNext
Back to top
Download PDF
Citation Tools
Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients
Melanie Roch, Maria Celeste Varela, Agustina Taglialegna, Warren E. Rose, Adriana E. Rosato
Antimicrobial Agents and Chemotherapy Aug 2018, 62 (9) e00956-18; DOI: 10.1128/AAC.00956-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients
Melanie Roch, Maria Celeste Varela, Agustina Taglialegna, Warren E. Rose, Adriana E. Rosato
Antimicrobial Agents and Chemotherapy Aug 2018, 62 (9) e00956-18; DOI: 10.1128/AAC.00956-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

cystic fibrosis
chronic infections
MRSA
telavancin

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596